Skip to content

Study · Animal study (in vivo) · rat · 2008

14 results

Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.

Larsen PJ, Wulff EM, Gotfredsen CF, Brand CL, Sturis J, Vrang N, Knudsen LB, Lykkegaard K

Diabetes, obesity & metabolism1 Apr 2008Cited by 25 (Europe PMC)

PMID18333889 (opens in a new tab)DOI10.1111/j.1463-1326.2008.00865.x (opens in a new tab)PepBankPUB-18333889
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In severely diabetic Zucker diabetic fatty rats, liraglutide alone gave HbA1c of 8.8% versus 9.7% with vehicle.

    In plain wordsIn diabetic rats, liraglutide alone gave lower HbA1c than vehicle.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c at day 28
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.4 mg/kg/day · 42 daysAs given in this study (rat).

    Measurements

    HbA1c
    8.8%
    liraglutide
    HbA1c
    9.7%
    vehicle

    Source sentences

    Summary
    Liraglutide and pioglitazone synergistically improved glycaemic control as reflected by a marked decrease in HbA(1C) (liraglutide + pioglitazone: 4.8 +/- 0.3%; liraglutide: 8.8 +/- 0.6%; pioglitazone: 7.9 +/- 0.4%; vehicle: 9.7 +/- 0.3%)
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In severely diabetic Zucker diabetic fatty rats, liraglutide alone gave a glucose AUC of 7164 mmol/l x min versus 8093 with vehicle.

    In plain wordsIn diabetic rats, liraglutide alone gave a lower glucose AUC after an oral glucose test than vehicle.

    Peptide
    Liraglutide
    Outcome
    DecreaseOral glucose tolerance AUC at day 42
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.4 mg/kg/day · 42 daysAs given in this study (rat).

    Measurements

    OGTT AUC
    7164 mmol/l x min
    liraglutide
    OGTT AUC
    8093 mmol/l x min
    vehicle

    Source sentences

    Summary
    and improved oral glucose tolerance at day 42 (area under the curve; liraglutide + pioglitazone: 4244 +/- 445 mmol/l x min; liraglutide: 7164 +/- 187 mmol/l x min; pioglitazone: 7430 +/- 446 mmol/l x min; vehicle: 8093 +/- 139 mmol/l x min).
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, the 24-h plasma glucose profile was significantly decreased only in the liraglutide plus pioglitazone group, not with liraglutide alone.

    In plain wordsIn diabetic rats, liraglutide alone did not significantly lower 24-hour blood glucose compared with vehicle.

    Peptide
    Liraglutide
    Outcome
    No significant change24-h plasma glucose profile at day 38
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.4 mg/kg/day · 42 daysAs given in this study (rat).

    Source sentences

    Summary
    A 24-h plasma glucose profile at day 38 was significantly decreased only in the liraglutide + pioglitazone group.
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, the 24-h insulin profile was significantly elevated only in the liraglutide plus pioglitazone group, not with liraglutide alone.

    In plain wordsIn diabetic rats, liraglutide alone did not significantly raise 24-hour insulin compared with vehicle.

    Peptide
    Liraglutide
    Outcome
    No significant change24-h insulin profile
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.4 mg/kg/day · 42 daysAs given in this study (rat).

    Source sentences

    Summary
    In addition, 24-h insulin profile was significantly elevated only in the liraglutide + pioglitazone group.
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, liraglutide alone significantly decreased food intake.

    In plain wordsIn diabetic rats, liraglutide alone reduced food intake.

    Peptide
    Liraglutide
    Outcome
    DecreaseFood intake
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.4 mg/kg/day · 42 daysAs given in this study (rat).

    Source sentences

    Summary
    Liraglutide significantly decreased food intake alone and in combination with pioglitazone, while pioglitazone alone increased cumulated food intake.
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, liraglutide alone gained significantly less weight than vehicle-treated rats.

    In plain wordsIn diabetic rats, liraglutide alone led to less weight gain than vehicle.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight gain
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.4 mg/kg/day · 42 daysAs given in this study (rat).

    Source sentences

    Summary
    As a result, rats on liraglutide alone gained significantly less weight than vehicle-treated rats,
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In severely diabetic Zucker diabetic fatty rats, adding liraglutide to pioglitazone gave HbA1c of 4.8% versus 7.9% with pioglitazone alone.

    In plain wordsIn diabetic rats, adding liraglutide to pioglitazone lowered HbA1c more than pioglitazone alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c at day 28, liraglutide added to pioglitazone
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Pioglitazone alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.4 mg/kg/day · 42 daysAs given in this study (rat).

    Measurements

    HbA1c
    4.8%
    liraglutide + pioglitazone
    HbA1c
    7.9%
    pioglitazone

    Source sentences

    Summary
    Liraglutide and pioglitazone synergistically improved glycaemic control as reflected by a marked decrease in HbA(1C) (liraglutide + pioglitazone: 4.8 +/- 0.3%; liraglutide: 8.8 +/- 0.6%; pioglitazone: 7.9 +/- 0.4%; vehicle: 9.7 +/- 0.3%)
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In severely diabetic Zucker diabetic fatty rats, adding liraglutide to pioglitazone gave a glucose AUC of 4244 mmol/l x min versus 7430 with pioglitazone alone.

    In plain wordsIn diabetic rats, adding liraglutide to pioglitazone improved glucose tolerance more than pioglitazone alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseOral glucose tolerance AUC at day 42, liraglutide added to pioglitazone
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Pioglitazone alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.4 mg/kg/day · 42 daysAs given in this study (rat).

    Measurements

    OGTT AUC
    4244 mmol/l x min
    liraglutide + pioglitazone
    OGTT AUC
    7430 mmol/l x min
    pioglitazone

    Source sentences

    Summary
    and improved oral glucose tolerance at day 42 (area under the curve; liraglutide + pioglitazone: 4244 +/- 445 mmol/l x min; liraglutide: 7164 +/- 187 mmol/l x min; pioglitazone: 7430 +/- 446 mmol/l x min; vehicle: 8093 +/- 139 mmol/l x min).
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 09AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In severely diabetic Zucker diabetic fatty rats, liraglutide plus pioglitazone gave HbA1c of 4.8% versus 9.7% with vehicle.

    In plain wordsIn diabetic rats, the liraglutide plus pioglitazone combination lowered HbA1c far below vehicle.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c at day 28, liraglutide plus pioglitazone
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c
    4.8%
    liraglutide + pioglitazone
    HbA1c
    9.7%
    vehicle

    Source sentences

    Summary
    Liraglutide and pioglitazone synergistically improved glycaemic control as reflected by a marked decrease in HbA(1C) (liraglutide + pioglitazone: 4.8 +/- 0.3%; liraglutide: 8.8 +/- 0.6%; pioglitazone: 7.9 +/- 0.4%; vehicle: 9.7 +/- 0.3%)
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 10AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In severely diabetic Zucker diabetic fatty rats, liraglutide plus pioglitazone gave a glucose AUC of 4244 mmol/l x min versus 8093 with vehicle.

    In plain wordsIn diabetic rats, the liraglutide plus pioglitazone combination improved glucose tolerance versus vehicle.

    Peptide
    Liraglutide
    Outcome
    DecreaseOral glucose tolerance AUC at day 42, liraglutide plus pioglitazone
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    OGTT AUC
    4244 mmol/l x min
    liraglutide + pioglitazone
    OGTT AUC
    8093 mmol/l x min
    vehicle

    Source sentences

    Summary
    and improved oral glucose tolerance at day 42 (area under the curve; liraglutide + pioglitazone: 4244 +/- 445 mmol/l x min; liraglutide: 7164 +/- 187 mmol/l x min; pioglitazone: 7430 +/- 446 mmol/l x min; vehicle: 8093 +/- 139 mmol/l x min).
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 11AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In diabetic rats, the 24-h plasma glucose profile was significantly decreased only with liraglutide plus pioglitazone.

    In plain wordsIn diabetic rats, only the liraglutide plus pioglitazone combination significantly lowered 24-hour blood glucose.

    Peptide
    Liraglutide
    Outcome
    Decrease24-h plasma glucose profile at day 38, liraglutide plus pioglitazone
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    A 24-h plasma glucose profile at day 38 was significantly decreased only in the liraglutide + pioglitazone group.
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 12AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In diabetic rats, the 24-h insulin profile was significantly elevated only with liraglutide plus pioglitazone.

    In plain wordsIn diabetic rats, only the liraglutide plus pioglitazone combination significantly raised 24-hour insulin.

    Peptide
    Liraglutide
    Outcome
    Increase24-h insulin profile, liraglutide plus pioglitazone
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In addition, 24-h insulin profile was significantly elevated only in the liraglutide + pioglitazone group.
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 13AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In diabetic rats, liraglutide in combination with pioglitazone significantly decreased food intake.

    In plain wordsIn diabetic rats, the liraglutide plus pioglitazone combination reduced food intake.

    Peptide
    Liraglutide
    Outcome
    DecreaseFood intake, liraglutide plus pioglitazone
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Liraglutide significantly decreased food intake alone and in combination with pioglitazone, while pioglitazone alone increased cumulated food intake.
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 14AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In diabetic rats, liraglutide plus pioglitazone caused the largest weight gain, probably reflecting improved energy balance from reduced glucosuria.

    In plain wordsIn diabetic rats, the liraglutide plus pioglitazone combination led to the largest weight gain.

    Peptide
    Liraglutide
    Outcome
    IncreaseBody weight gain, liraglutide plus pioglitazone
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    However, combination therapy with liraglutide and pioglitazone caused the largest weight gain, probably reflecting marked improvement of energy balance because of reduction of glucosuria.
    1 context sentence
    Summary · context
    Therapeutic benefits of combining the long-acting human glucagon-like peptide-1 (GLP-1) analog, liraglutide (0.4 mg/kg/day), with insulin sensitizer, pioglitazone (10 mg/kg/day), were assessed in severely diabetic Zucker diabetic fatty rats for 42 days.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.